SCHEMBL5293227

SCHEMBL5293227

O=S(=O)(Nc1cccc(F)c1F)c1ccc(F)c2nonc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.54
POLB P06746 2/20 0.54
GFER P55789 1/20 0.48
ALDH1A1 P00352 3/20 0.47
MAPT P10636 2/20 0.47
LMNA P02545 1/20 0.47
GAA P10253 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PTGES2 Q9H7Z7 2/20 0.47
PIK3CD O00329 2/20 0.44
PIK3CA P42336 2/20 0.44
PIK3CB P42338 2/20 0.44
PIK3CG P48736 2/20 0.44
SLC40A1 Q9NP59 4/20 0.42
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAPK1 P28482 1/20 0.40
SLC22A12 Q96S37 1/20 0.39
ACLY P53396 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5282982 0.88 PIK3CD (0.52) KMT2APOLBGFERALDH1A1MAPT
SCHEMBL6395928 0.85 KMT2A (0.70) KMT2APOLBGFERALDH1A1MAPT
SCHEMBL5278068 0.80 KMT2A (0.43) KMT2APOLBGFERALDH1A1MAPT
SCHEMBL5294930 0.79 ALDH1A1 (0.52) KMT2APOLBGFERALDH1A1MAPT
SCHEMBL14433267 0.79 KMT2A (0.72) KMT2APOLBGFERALDH1A1MAPT
SCHEMBL5295903 0.78 SLC40A1 (0.50) KMT2APOLBALDH1A1MAPTLMNA
SCHEMBL6396242 0.78 POLB (0.41) KMT2APOLBGFERALDH1A1MAPT
SCHEMBL6392197 0.78 KMT2A (0.47) KMT2APOLBGFERALDH1A1MAPT
SCHEMBL5243227 0.77 KMT2A (0.56) KMT2APOLBALDH1A1SMN1; SMN2
SCHEMBL5295964 0.77 POLB (0.50) KMT2APOLBGFERALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US claimed
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 WO disclosed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP KMT2A 1303/4885POLB 2997/4885GFER 2796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.